Back HIV/AIDS

HIV / AIDS

CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look promising in larger studies, according to a presentation at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

CROI 2017: STI Rates Among PrEP Users Are High, But Evidence that PrEP Increases Them Is Inconclusive

A study of pre-exposure prophylaxis (PrEP) users presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle showed that they had very high rates of sexually transmitted infection (STI) diagnosis -- on the order of 20 times higher than among HIV-negative gay men in the general population. However, it is unclear whether STIs increased further after people went on PrEP.

alt

CROI 2017: Efavirenz/ Tenofovir/Emtricitabine Less Likely to Cause Adverse Birth Outcomes

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine, and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to those exposed to other 3-drug regimens, according to a study of births in Botswana presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options

A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells -- ibalizumab and PRO 140 -- may offer new treatment options for people with highly resistant virus and limited treatment options, researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

CROI 2017: Unique Case of PrEP Failure Without Drug Resistance Reported in Amsterdam

HIV pre-exposure prophylaxis (PrEP) appears to be nearly 100% effective if taken consistently. However, among tens of thousands of cases of PrEP preventing HIV, there have been a few reports of people who acquired HIV despite high adherence to PrEP and adequate drug levels, including one reported in a poster at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) last week in Seattle.

alt

CROI 2017: Science, Community, and Political Will Can End HIV Epidemic, Says New York Commissioner

New York City’s strategy to end the HIV/AIDS epidemic is firmly rooted in science, was developed in conjunction with community activists, and has support from top-level political leaders, Demetre Daskalakis told a plenary audience at the Conference on Retroviruses and Opportunistic Infections last week in Seattle. "When you combine political will, biological interventions, and harm reduction, you can get to zero," he said.

alt

CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study

Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a Phase 3 clinical trial of people starting antiretroviral therapy (ART) for the first time, but it had a better lipid profile, according to a late-breaking presentation at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.

alt